À¯±¤ÇÏ ¸íÀÇ

¸¸¼ºÆó¼â¼ºÆóÁúȯ Áø·á ¹× ¿¬±¸ÀÇ ¼±µÎ ÁÖÀÚ

À¯±¤ÇÏ ¸íÀÇ

  • ¼Ò ¼Ó
    °Ç±¹´ëÇб³º´¿ø ¾Ë·¹¸£±â³»°ú,È£Èí±â³»°ú
  • Àü¹®ºÐ¾ß
    ¸¸¼ºÆó¼â¼ºÆóÁúȯ, ±â°üÁöõ½Ä

À¯±¤ÇÏ º´¿øÀåÀº °Ç±¹´ëº´¿ø¿¡¼­ È£Èí±â-¾Ë·¹¸£±â³»°ú ±³¼ö·Î ÀçÁ÷Çϸ鼭 Áø·áºÎ¿øÀå°ú º´¿øÀåÀ» ¿ªÀÓÇß´Ù. ÇöÀç ´ëÇѰáÇÙ ¹× È£Èí±âÇÐȸ ÀÌ»çÀåÀ¸·Î, Ãѹ«ÀÌ»ç¿Í COPD ¿¬±¸È¸ ȸÀå µîÀ» ¿ªÀÓÇß´Ù. COPD ¸íÀǷμ­ ȯÀÚ¸¦ À§ÇØ °ü·Ã ºÐ¾ßÀÇ Áø·á¿Í ¿¬±¸¸¦ Ȱ¹ßÈ÷ Çϰí ÀÖ´Ù. Áö³­ 2023³â¿¡´Â ICS(ÈíÀÔ½ºÅ×·ÎÀ̵å)+LABA º´¿ë¿ä¹ý ´ëºñ LAMA »ç¿ë ÀÌÁ¡À» È®ÀÎÇÑ ÀÓ»ó ¿¬±¸·Î ±¹Á¦Àû ÁÖ¸ñÀ» ¹Þ¾Ò´Ù. ¶Ç À¯±¤ÇÏ º´¿øÀåÀÌ ÁøÇàÇÑ COPD ÄÚȣƮ ¿¬±¸´Â COPD ȯÀÚÀÇ È£ÈíÀçȰ°ú À̵¿½Ä »ê¼Ò Ä¡·á¸¦ °Ç°­º¸ÇèÀû¿ëÇ׸ñÀ¸·Î ¸¸µé¸ç ȯÀÚ ±³À°À» À§ÇÑ Á¦µµÀû ¿©°ÇÀ» ¸¶·ÃÇß´Ù´Â Æò°¡¸¦ ¹Þ¾Ò´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °í·Á´ëÇб³ Àǰú´ëÇпø ¹Ú»ç
  • °Ç±¹´ëÇб³ Àǰú´ëÇпø ¼®»ç
  • ÇѾç´ëÇб³ Àǰú´ë Çлç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °Ç±¹´ëÇб³º´¿ø º´¿øÀå
  • úÞ) °Ç±¹´ëÇб³º´¿ø ±³¼ö

¼ö»ó³»¿ª

Awards List
  • 2017 º¸°Çº¹ÁöºÎÀå°ü ǥâ (Á¦114640È£)
  • 2013 º¸°Çº¹ÁöºÎÀå°ü ǥâ (Á¦90661È£)

ÇÐȸȰµ¿

Academic activities
  • 2025.1 ~ ÇöÀç´ëÇѰáÇÙ ¹× È£Èí±â ÇÐȸ ÀÌ»çÀå
  • 2023.1 ~ 2024.12´ëÇѰáÇÙ ¹× È£Èí±â ÇÐȸ ¹«ÀÓ¼Ò ÀÌ»ç
  • 2021.1 ~ 2022.12´ëÇѰáÇÙ ¹× È£Èí±â ÇÐȸ Ãѹ« ÀÌ»ç
  • 2019.1 ~ 2020.12´ëÇѰáÇÙ ¹× È£Èí±â ÇÐȸ Çмú ÀÌ»ç
  • 2017.1 ~ 2018.12´ëÇѰáÇÙ ¹× È£Èí±â ÇÐȸ °£Çà ÀÌ»ç
õ½Ä°ú ¾Ë·¹¸£±âÁúȯ
´ëÇ¥¼­Àû

õ½Ä°ú ¾Ë·¹¸£±âÁúȯ

  • ÀúÀÚ(±Û)´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ
  • ÃâÆÇ»ç¿©¹®°¢
  • ¹ßÇàÀÏ2012³â 03¿ù 30ÀÏ
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 2°Ç
Á¦ ¸ñ 4õ¸¸ÀÇ ¾Ë·¹¸£±â
ÃâÆÇ»ç °øÀúÀÚ ¹ßÇàÀÏ 1993³â ¹ß°£, 2005³â °³Á¤
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Blood eosinophil count and treatment patterns of chronic obstructive pulmonary disease patients in South Korea using real-world data
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö ±³½ÅÀúÀÚ
Á¦ ¸ñ Kernel conversion improves correlation between emphysema extent and clinical parameters in COPD: a multicenter cohort study
¹ßÇ¥³âµµ 2025 ¹ßÇ¥Áö ±³½ÅÀúÀÚ
Á¦ ¸ñ Clinical characteristics of chronic obstructive pulmonary disease patients with superoptimal peak inspiratory fow rate
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö ±³½ÅÀúÀÚ
Á¦ ¸ñ Efficacy and safety of mixture of ivy leaf extract and coptidis rhizome in the treatment of acute bronchitis: multicenter, randomized, double blinded, active-controlled, parallel, therapeutic confirmatory clinical trial
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö ±³½ÅÀúÀÚ
Á¦ ¸ñ Clinical Characteristics and Frequency of Chronic Obstructive Pulmonary Disease Exacerbations in Korean Patients: Findings From the KOCOSS Cohort 2012–2021
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö ±³½ÅÀúÀÚ
Á¦ ¸ñ Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö ±³½ÅÀúÀÚ
Á¦ ¸ñ Short-acting ¥â2-agonist prescriptions in patients with asthma: findings from the South Korean cohort of SABINA III
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö ÁÖÀúÀÚ

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

[°ü½ÉºÐ¾ß] ±¹³» ¸¸¼ºÆó¼â¼ºÆóÁúȯ ÀÎÁöµµ Çâ»ó ¹× ¿Ã¹Ù¸¥ Ä¡·á¿¡ ÀÇÇÑ °Ç°­ ºÎ´ã °¨¼Ò
[¾÷Àû] Àü±¹ 52°³ º´¿øÀÌ Âü¿©ÇÑ ¸¸¼ºÆó¼â¼ºÆóÁúȯ ÄÚȣƮ ¿¬±¸Ã¥ÀÓÀÚ·Î ±¹³» ¸¸¼ºÆó¼â¼ºÆóÁúȯ ¿¬±¸ÀÇ ¼±µÎÁÖÀÚÀÓ

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

ȯÀÚÀÇ Áúº´ Ä¡·á¿Í ¸¶À½ÀÇ À§¾ÈÀ» ÇÔ²² Á¦°øÇÔ. ȯÀÚ°¡ Áø·á½Ç¿¡ Ç×»ó ¿õ½º¸é¼­ µé¾î¿À°í ¿ôÀ¸¸é¼­ ³ª°¥ ¼ö ÀÖµµ·Ï ³ë·ÂÇÔ

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

Áúº´Àº ȯÀÚÀÇ À߸øÀÌ ¾Æ´Õ´Ï´Ù. ³«½ÉÇÏÁö ¾Ê°í ¿­½ÉÈ÷ Ä¡·á¿Í ÀçȰÀ» Çϸé ȸº¹ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°Ç±¹´ëÇб³º´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-1533
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°Ç±¹´ëÇб³º´¿øÀº »óÇã À¯¼®Ã¢ ¼±»ý²²¼­ ÀÏÁ¦ °­Á¡±âÀÎ 1931³â ¹ÎÁ·ÁöµµÀÚµé°ú ¶æÀ» ¸ð¾Æ ±¸·áÁ¦¹Î(Ï­Öûð­ÚÅ)°ú Àμúº¸±¹(ìÒâúÜÃÏÐ)ÀÇ Å« ¶æÀ» ´ã¾Æ ¼³¸³ÇÑ ¡®»çȸ¿µ Á߾ӽǺñÁø·á¿ø¡¯¿¡ »Ñ¸®¸¦ µÎ°í ÀÖ´Ù. 2002³â °Ç±¹´ëÇб³ ¼­¿ïÄ·ÆÛ½º ³²´Ü¿¡ º´¿ø °Ç¹°À» »õ·Î Áþ±â ½ÃÀÛÇØ 2005³â 8¿ù »õ·Ó°Ô žÀ¸¸ç ÁöÇÏ4Ãþ, Áö»ó 13Ãþ ¿¬¸éÀû 2¸¸ 6300¿©ÆòÀÇ »õ °Ç±¹´ëº´¿øÀº 33°³ÀÇ Áø·á°ú¿Í 784°³ÀÇ º´»ó, 9°³ÀÇ ÁßÁ¡¼¾ÅÍ¿Í 14°³ÀÇ Áø·á¼¾ÅÍ, ÇコÄɾÅ͸¦ °®Ãß°í 430¿©¸íÀÇ ÀÇ·áÁøÀÌ Áø·á¸¦ Çϰí ÀÖ´Ù. 2009³â °©»ó¼±¾Ï¼¾ÅÍ, ´ëÀå¾Ï¼¾ÅÍ, À¯¹æ¾Ï¼¾ÅÍ µî ¾Ï¼¾Å͸¦ °³¼³Çϰí, 2017³â 11¿ù¿¡´Â ÃÖ½ÅÇü ·Îº¿ ¸ðµ¨ÀÎ 4¼¼´ë ´ÙºóÄ¡Xi¸¦ µµÀÔ, ·Îº¿¼ö¼ú ¼¾ÅÍ °¡µ¿À» ½ÃÀÛÇß´Ù. °Ç±¹´ëº´¿øÀº ´ëÀå¾Ï, À¯¹æ¾Ï, Æó¾Ï, À§¾Ï, Ç÷¾×Åõ¼®, ¸¸¼ºÆó¼â¼ºÆóÁúȯ µî ÁßÁõÁúȯ ºÐ¾ß Æò°¡¿¡¼­ 1µî±ÞÀ» ±â·ÏÇϰí ÀÖÀ¸¸ç, °ñµçŸÀÓÀÌ Áß¿äÇÑ ½ÉÇ÷°üÁúȯ°ú ³úÇ÷°üÁúȯÀÇ ½Å¼ÓÁø·á½Ã½ºÅÛÀ» ¿î¿µÇÏ¸ç ±Þ¼º±â ³úÁ¹Áß ¹× °ü»óµ¿¸Æ¿ìȸ¼ú Æò°¡¿¡¼­µµ 1µî±ÞÀ» À̾°í ÀÖ´Ù. Áö³­ 2023³â¿¡´Â ÁßÁõÁúȯ Ä¡·á ¿ª·® °­È­¸¦ À§ÇØ ÁßȯÀÚ½Ç ¹× ¼ö¼ú½Ç Áõ¼³, ·Îº¿¼ö¼ú±â±â Ãß°¡ ¹× CTµî ½ÅÇüÀÇ·áÀåºñ µîÀ» µµÀÔÇß´Ù. À̾î 2024³â¿¡´Â ȯÀÚµéÀÇ ÄèÀûÇÑ È¯°æÀ» À§ÇØ º´µ¿ ȯ°æÀ» °³¼±Çϰí, 2025³â¿¡´Â ¿Ü·¡¼¾ÅÍ ÁõÃàÀ» ¾ÕµÎ°í ÀÖ´Ù.

°Ç±¹´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã ±¤Áø±¸ ´Éµ¿·Î 120-1(È­¾çµ¿) °Ç±¹´ëÇб³º´¿ø

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä